SIGA Technologies

SIGA Technologies EBIT per Share

The EBIT per Share of SIGA Technologies (SIGA) as of Nov 3, 2026 is 0.33 USD. In the previous year, EBIT per Share was 0.98 USD — a change of -66.06% (lower).

EBIT per Share

0.33USD

YoY

-66.06%

Last updated:

EBIT per Share of SIGA Technologies is 2025 0.33 USD. EBIT per Share of SIGA Technologies was 2024 0.98 USD. It decreases by -66.06% lower compared to the previous year.

The SIGA Technologies EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2020
1.08 USD
Jan 1, 2021
1.19 USD
Jan 1, 2022
0.59 USD
Jan 1, 2023
1.18 USD
Jan 1, 2024
0.98 USD
Jan 1, 2025
0.33 USD
Jan 1, 2026 (e)
0.00 USD
Jan 1, 2027 (e)
1.40 USD
The SIGA Technologies EBIT per Share history
YEAREBIT per ShareYoY
est1.40USD—
est0.00USD-100.00%
0.33USD-66.06%
0.98USD-17.10%
1.18USD+100.27%
0.59USD-50.78%
1.19USD+10.27%
1.08USD-3,886.16%
-0.03USD-100.65%
4.39USD-1,571.60%
-0.30USD-8.30%
-0.33USD-43.14%
-0.57USD-85.40%
-3.92USD+787.39%
-0.44USD+1.34%
-0.44USD-28.29%
-0.61USD+138.65%
-0.25USD-7.40%
-0.27USD+12.80%
-0.24USD+10.89%
-0.22USD+5.21%
-0.21USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SIGA Technologies Stock analysis

What does SIGA Technologies do? SIGA Technologies Inc was founded in 1995 and is headquartered in New York, USA. The company specializes in developing, producing, and distributing medical solutions for viral diseases, particularly for the treatment of smallpox. SIGA Technologies' business model is based on the development of antiviral drugs and vaccines that help in the treatment and prevention of infectious diseases. The company has a wide range of technologies and knowledge to develop innovative products. The focus is on researching viral diseases to find new treatment options and make them accessible. The company has several divisions that focus on different areas of virus infection treatment. The first division focuses on the treatment of smallpox. The company has produced the first approved medication for smallpox, Tecovirimat. Tecovirimat is an antiviral drug used for the treatment of smallpox. It is the only medication approved by the US Food and Drug Administration (FDA) for the treatment of smallpox. Another division of SIGA Technologies is dedicated to the development of antiviral agents that can control the spread of diseases such as Ebola, Lassa fever, and other viral diseases. The company has several promising drugs in the pipeline to meet the global demand for antiviral medications. SIGA Technologies also has innovative products in the diagnostics division. The company has developed a platform technology that allows for rapid and accurate diagnosis of virus infections. The platform, called AmpliPhi is Thermal Unwinding (AITU) technology, enables the diagnosis of a variety of virus infections and allows for targeted treatment to be initiated quickly. These tests can be performed both in laboratories and on-site, making them particularly valuable for use in medical facilities in rural areas or highly affected areas. Overall, SIGA Technologies has a broad portfolio of products and solutions for the treatment and prevention of virus infections. The company has an experienced and knowledgeable team of scientists and experts in this field, continuously driving new developments. SIGA Technologies is committed to making a contribution to improving global health and to having positive impacts on public health through its products and services. SIGA Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SIGA Technologies stock

EBIT per Share of SIGA Technologies is 0.33 USD in 2025.

EBIT per Share of SIGA Technologies changed from 0.98 USD to 0.33 USD, representing a -66.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share SIGA Technologies since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — SIGA Technologies

All Key Metrics — SIGA Technologies